News
INVO Bioscience Announces $4.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SARASOTA, Fla., Oct. 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, today announced that it has entered into definitive agreements with...
INVO Bioscience Advances INVOcell® Commercialization Efforts With Acquisition in Canada
Provides platform to leverage the existing INVOcell product registration in Canada and ongoing work with leading embryologist, Ric Ross, to establish INVO Centers and enhance distribution into existing fertility clinicsSARASOTA, Fla., Sept. 9, 2021 /PRNewswire/ --...
INVO Bioscience Announces Official Opening of “Bloom Fertility, an INVO Center” in Atlanta
Bloom Fertility, An INVO Center becomes the second JV-owned clinic focused on providing INVOcell to assist the underserved patients in need of advanced fertility careSARASOTA, Fla. and ATLANTA, Sept. 7, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a...
Dr. Inger Britt Carlsson, Vice President of Global Medical Affairs for INVO Bioscience, to Present at the 11th Annual AFRH Virtual Conference
Dr. Carlsson will be speaking on the topic of INVOcell® as an efficient, patient-centric fertility solution for the growing demand in AfricaSARASOTA, Fla., Sept. 3, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on...
INVO Bioscience Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update
Company to Host Conference Call Today at 4:30pm ET (Details Below)SARASOTA, Fla., Aug. 16, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and...
INVO Bioscience to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ETSARASOTA, Fla., Aug. 5, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture...
INVO Bioscience Announces First Joint-Venture Grand Opening Scheduled for August 9, 2021 in Birmingham, Alabama
Innovative Fertility Specialists, An INVO Center becomes the first JV-owned clinic focused on providing INVOcell to assist the underserved patients in need of advanced fertility careSARASOTA, Fla., Aug. 2, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a...
INVO Bioscience Appoints Barbara Levy as Senior VP, Global Clinical Integration
Joins INVO Bioscience to accelerate INVOcell's global OB/GYN clinical integration strategySARASOTA, Fla., July 14, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture System...
INVO Bioscience Signs Joint Venture Agreement with Bloom Fertility to Open an INVOcell Fertility Clinic in Atlanta
INVO Bioscience and established reproductive specialist Dr. Sue Ellen Carpenter, MD of Bloom Fertility today announce their partnership to make INVOcell, an innovative technology that allows early embryo development to take place within the woman's body, more...
INVO Bioscience Appoints Andrea Goren as Chief Financial Officer
SARASOTA, Fla., June 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients...